Search results
Results From The WOW.Com Content Network
File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.
Revenue. $1.921 billion (2005) Number of employees. 5,400 (2005) Website. www.chiron.com. Chiron Corporation ( / ˈkaɪrɒn / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five ...
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Novartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patients in clinical trials, and building ...
Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...
The Novartis Foundation was a scientific and educational charity, formed in 1949 by the Swiss company Ciba, now Novartis, and dissolved in 2008. It was the direct successor to the Ciba Foundation, and the changed name (Novartis Foundation) reflected the new name of Ciba, after merging with Sandoz. The Foundation was the brainchild of Robert ...
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ). [9] [7]
Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.